2018
The Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M
Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Song H, Choe S, Kim D, Kim S, Ha Y, Moon S, Lee G, Kim I, Yun S, Kim W. The Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M. The American Journal Of Chinese Medicine 2018, 46: 689-705. PMID: 29595070, DOI: 10.1142/s0192415x18500362.Peer-Reviewed Original ResearchConceptsCentromere protein MBladder cancerBC patientsGarlic extractBetter progression-free survivalNude mouse xenograft modelProgression-free survivalCisplatin-treated miceBALB/cTissue microarray analysisNegative control miceMouse xenograft modelBC cell linesEffect of garlicMicroarray analysisCisplatin groupControl miceTumor weightControl tumorsTumor volumeNormal controlsXenograft modelSide effectsBody weightTumor tissue
2017
Intracrine androgen biosynthesis in renal cell carcinoma
Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Ahn H, Kim W, Kim I. Intracrine androgen biosynthesis in renal cell carcinoma. British Journal Of Cancer 2017, 116: 937-943. PMID: 28253524, PMCID: PMC5379152, DOI: 10.1038/bjc.2017.42.Peer-Reviewed Original ResearchMeSH KeywordsAbiraterone AcetateAndrogensAnimalsAntineoplastic AgentsApoptosisBenzamidesBlotting, WesternCarcinoma, Renal CellCell ProliferationDihydrotestosteroneFemaleHumansImmunoenzyme TechniquesKidney NeoplasmsMaleMiceMice, NudeNitrilesOrchiectomyPhenylthiohydantoinPrognosisProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReal-Time Polymerase Chain ReactionReceptors, AndrogenReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTestosteroneTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsRenal cell carcinomaCastration-resistant prostate cancerRCC cell linesAnti-androgen therapyHuman RCC cell linesAndrogen biosynthesisAbiraterone acetateCell carcinomaAndrogen receptorTumor volumeCell linesAndrogen deprivation therapyHigher tumor stageProstate cancer patientsMouse xenograft studiesGenitourinary cancersTumor suppressionSignificant tumor suppressionRCC patientsTumor stageCancer patientsMale miceProstate cancerIntratumoral steroidogenesisXenograft studies
2016
BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon Y, Zhong H, Medina D, Kerrigan J, Stein M, Kim I, Davis T, DiPaola R, Bertino J, Sabaawy H. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer. Clinical Cancer Research 2016, 22: 6176-6191. PMID: 27307599, PMCID: PMC5159329, DOI: 10.1158/1078-0432.ccr-15-3107.Peer-Reviewed Original ResearchConceptsTumor-initiating cellsProstate tumor-initiating cellsBmi-1Androgen receptor-directed therapyIntrinsic therapy resistanceReceptor-directed therapyProstate cancer managementProstate cancer treatmentMore effective therapiesBmi-1 expressionProstate cancer cellsStem cell-like traitsSelf-renewing tumor-initiating cellsCell-like traitsPatient-derived cellsEffective therapyTumor relapseCancer managementXenograft modelTherapy resistancePharmacologic inhibitionBmi-1 functionTherapyNormal tissuesCancer treatment
2015
Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer
Han C, Patel R, Kim I. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Expert Opinion On Drug Metabolism & Toxicology 2015, 11: 967-975. PMID: 25936418, DOI: 10.1517/17425255.2015.1041918.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerMetastatic castration-resistant prostate cancerAbiraterone acetateMetastatic CRPCProstate cancerPhase III trialsBetter patient selectionHigh-level evidenceRisk of hypertensionDrug resistance patternsCurrent clinical challengesIntratumoral androgensOverall tolerabilityIII trialsPatient selectionClinical efficacySafety profileDevelopment of resistanceTreatment modalitiesDisease progressionTargeted therapyAndrogen sourceClinical challengeAndrogen signalingCYP 17
2014
Enzalutamide: looking back at its preclinical discovery
Ha Y, Kim I. Enzalutamide: looking back at its preclinical discovery. Expert Opinion On Drug Discovery 2014, 9: 837-845. PMID: 24820058, DOI: 10.1517/17460441.2014.918947.Peer-Reviewed Original ResearchConceptsCastration-recurrent PCaFirst-line therapyProstate cancerClinical developmentCastration-recurrent prostate cancerStandard first-line therapyAndrogen-AR axisAR agonist activityMetastatic prostate cancerAR nuclear translocationSelective AR modulatorsFurther clinical studiesAndrogen receptor antagonistPre-clinical discoveryDrug clinical developmentSequential therapyOverall survivalTargeted agentsReceptor antagonistClinical studiesPreclinical discoveryNew agentsAR modulatorsAgonist activityFDA approval
2013
Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung J, Ha Y, Kim I. Radium Ra 223 dichloride in castration-resistant prostate cancer. Drugs Of Today 2013, 49: 483-90. PMID: 23977665, DOI: 10.1358/dot.2013.49.8.1968670.Peer-Reviewed Original ResearchConceptsRadium Ra 223 dichlorideCastration-resistant prostate cancerRa-223 dichlorideBone metastasesProstate cancerLarge randomized phase III trialsRandomized phase III trialMedian overall survivalPhase III trialsPlacebo groupIII trialsOverall survivalPreclinical studiesAntitumor effectsBone marrowCanine modelHigh biological effectPatientsMetastasisCancerBiological effectsKBq/Low toxicityRatsMarrow
2006
Expression of estrogen receptors‐α and ‐β in bladder cancer cell lines and human bladder tumor tissue
Shen S, Smith C, Hsieh J, Yu J, Kim I, Jian W, Sonpavde, Ayala G, Younes M, Lerner S. Expression of estrogen receptors‐α and ‐β in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006, 106: 2610-2616. PMID: 16700038, DOI: 10.1002/cncr.21945.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBlotting, WesternCarcinoma, Transitional CellCell Line, TumorCell ProliferationEstradiolEstrogen Receptor alphaEstrogen Receptor betaFulvestrantGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMicroarray AnalysisNeoplasm StagingRaloxifene HydrochlorideReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTamoxifenUrinary Bladder NeoplasmsConceptsBladder cancer cell linesExpression of ERbetaCancer cell linesERbeta expressionHuman bladder cancerBladder cancer cellsBladder cancerEstrogen receptorWestern blot analysisT4 tumorsCell linesMetastatic transitional cell carcinomaMuscle-invasive bladder cancerER-alpha mRNA levelsT3/T4 tumorsHuman bladder tumor tissuesRT4 cellsBladder cancer cell growthLevels of ERalphaGrade 3 tumorsCancer cellsInvasive bladder cancerTa/T1Transitional cell carcinomaEffects of estradiol
2002
Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*
Kim H, Kim B, Kim I, Mamura M, Seong H, Jang J, Kim S. Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*. Journal Of Biological Chemistry 2002, 277: 32510-32515. PMID: 12084714, DOI: 10.1074/jbc.m202852200.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid Chloromethyl KetonesAntineoplastic AgentsApoptosisBcl-Associated Death ProteinBcl-X ProteinCarrier ProteinsCaspase 3CaspasesCell DivisionCell MembraneCell NucleusCycloheximideCytochrome c GroupDNA FragmentationDose-Response Relationship, DrugEstrogen Receptor ModulatorsHumansIn Situ Nick-End LabelingMembrane PotentialsMitochondriaPhosphorylationProtein BindingProtein Synthesis InhibitorsProto-Oncogene Proteins c-bcl-2Raloxifene HydrochlorideRetroviridaeTime FactorsTumor Cells, CulturedUrinary Bladder NeoplasmsConceptsMixed estrogen agonist/antagonistTSU-Pr1 cell linesEstrogen agonist/antagonistTSU-Pr1 cellsAgonists/antagonistsCell linesSelective estrogen receptor modulatorsHuman bladder transitional cell carcinoma cell lineEffects of raloxifeneTransitional cell carcinoma cell linesProstate cancer cell linesEstrogen receptor modulatorsCell carcinoma cell linesEstrogen receptor betaHuman bladder cancerDose-dependent mannerEvidence of apoptosisCancer cell linesRaloxifene treatmentCarcinoma cell linesBladder cancerReceptor modulatorsBreast cancerHuman cancer cellsRaloxifene